Contradictory to the present study findings, non-significantly altered levels of CYP3A abundance (measured by an immunoblot technique, without discrimination of CYP3A4 and CYP3A5 isoforms) were provided by George et al. (for cholestatic liver diseases) and Guengerich et al. [13,14]. This evidence concerns the gene CYP3A4 and Cholestatic liver disease.